How can biosimilars best leverage real-world evidence in their operations? Anita Burrell Consulting LLC. Principal Anita Burrell takes a look at the subject in a column published Monday on BioProcess Online.
Burrell says biosimilars upon entry in the market “rarely” bring about the “highly anticipated cost savings,” primarily due to provider reluctance over a switch from originator products.
Pfizer Global President for Biosimilars Richard Blackburn during a press briefing, Burrell notes, that the need exists for education about biosimilars to clear up misinformation.
“Here RWE can demonstrate the product performance and management of disease in practice do not alter significantly from originator to biosimilar,” Burrell writes.